

02.28.2020

Dear Parent:

Toddlers aged 12-36 months are being invited to participate in a research study at Tanner Clinic and other sites across the nation to test the safety and immunogenicity of an investigational combination vaccination against both Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3). Both hMPV and PIV3 are known to cause upper and lower respiratory disease in people of all ages, with an increased risk of disease in young children. For more information about hMPV and PIV3, please review the enclosed brochure.

This study will evaluate the safety and immunogenicity of this vaccine when administered to children 12-36 months of age who have been previously exposed to both hMPV and PIV3. This study is comprised of a total of eight in-office visits, and 12 phone calls, over a period of 14 months. Participation will include two vaccinations, five blood draws, collection of vital signs, a medical history evaluation, and physical exams. You will be compensated for your time and travel. The results of this study may help researchers learn whether the investigational vaccine is safe, tolerable and effective in toddlers.

Your child may qualify for this study if he or she is between 12 and 36 months old when beginning the study and:

- Has received routine immunizations appropriate for their age per the Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP).
- Current height and weight above the third percentile for age.

There are additional criteria your child must meet in order to participate, and the study doctor can discuss this with you and answer any questions you may have.

- Study related care and the study vaccine will be provided at no cost.
- Eligible children are reimbursed for time and/or travel for completed study clinic visits up to \$1,250.

If you would like to learn more about this research study, including possible risks and benefits of participation, or to schedule an appointment, please call at 801.773.4840 and speak with Melanie Gibb, Clinical Research Director, at ext. 3741. I am also available to discuss the study with you and answer your questions. Thank you.

Sincerely,

Brent Eberhard, MD
Nathan Forbush, MD
Davin Hansen, PA-C
Adam Hutchinson, Sr. MD